Exercise

Oncology·MeSH: Motor Activity

24 drugs in development·15 companies·8 clinical trials

Drug Pipeline by Phase

Approved(20)

Drug	Company
adcirca	ELI LILLY & Co (LLY)
ambrisentan	Mylan II B.V. (MYL)
colesevelam	Impax Laboratories, LLC (IPXL)
epoprostenol	Mylan II B.V. (MYL)
exenatide synthetic	Amneal Pharmaceuticals, Inc. (AMRX)
exforge hct	Novartis AG (NVS)
letairis	GILEAD SCIENCES, INC. (GILD)
linagliptin	Mylan II B.V. (MYL)
losartan	Teva Pharmaceutical Industries Limited (TEVA)
metformin	Inventiva S.A. (IVA)
Mounjaro	ELI LILLY & Co (LLY)
Mounjaro®	ELI LILLY & Co (LLY)
nebivolol	ANI PHARMACEUTICALS INC (ANIP)
olmesartan medoxomil	Amneal Pharmaceuticals, Inc. (AMRX)
ozempic	Novo Nordisk A/S (NVO)
phendimetrazine	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
revatio	Viatris Inc (VTRS)
saxagliptin	Mylan II B.V. (MYL)
telmisartan	Inventiva S.A. (IVA)
treprostinil	Teva Pharmaceutical Industries Limited (TEVA)

Unknown(2)

Drug	Company
Equine All-in-One™	BIOADAPTIVES, INC. (BDPT)
Equine Regen®	BIOADAPTIVES, INC. (BDPT)

Early Phase 1(1)

Drug	Company
Carbon Dioxide	Valneva SE (VALN)

Phase 4(1)

Drug	Company
Epoetin Alfa	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 24 drugs in development for Exercise across 15 companies.

There are 8 clinical trials targeting Exercise tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.